![c-Met expression and activity in urogenital cancers – novel aspects of signal transduction and medical implications | Cell Communication and Signaling | Full Text c-Met expression and activity in urogenital cancers – novel aspects of signal transduction and medical implications | Cell Communication and Signaling | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12964-017-0165-2/MediaObjects/12964_2017_165_Fig1_HTML.gif)
c-Met expression and activity in urogenital cancers – novel aspects of signal transduction and medical implications | Cell Communication and Signaling | Full Text
![Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies - Cancer Treatment Reviews Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies - Cancer Treatment Reviews](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/d2e9375b-d9e8-46c1-87ed-1a6026e34c25/gr1.jpg)
Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies - Cancer Treatment Reviews
![HGF/Met Signaling in Head and Neck Cancer: Impact on the Tumor Microenvironment | Clinical Cancer Research HGF/Met Signaling in Head and Neck Cancer: Impact on the Tumor Microenvironment | Clinical Cancer Research](https://clincancerres.aacrjournals.org/content/clincanres/22/16/4005/F1.large.jpg)
HGF/Met Signaling in Head and Neck Cancer: Impact on the Tumor Microenvironment | Clinical Cancer Research
![Enzyme-mediated depletion of serum l-Met abrogates prostate cancer growth via multiple mechanisms without evidence of systemic toxicity | PNAS Enzyme-mediated depletion of serum l-Met abrogates prostate cancer growth via multiple mechanisms without evidence of systemic toxicity | PNAS](https://www.pnas.org/content/117/23/13000/F1.large.jpg)
Enzyme-mediated depletion of serum l-Met abrogates prostate cancer growth via multiple mechanisms without evidence of systemic toxicity | PNAS
![3 The theory of epithelial-mesenchymal transition (EMT). During the... | Download Scientific Diagram 3 The theory of epithelial-mesenchymal transition (EMT). During the... | Download Scientific Diagram](https://www.researchgate.net/profile/Qian-Xie-9/publication/322197224/figure/fig3/AS:578107772211201@1514843041773/The-theory-of-epithelial-mesenchymal-transition-EMT-During-the-progression-of-cancer.png)
3 The theory of epithelial-mesenchymal transition (EMT). During the... | Download Scientific Diagram
![MET Signaling: Novel Targeted Inhibition and Its Clinical Development in Lung Cancer - Journal of Thoracic Oncology MET Signaling: Novel Targeted Inhibition and Its Clinical Development in Lung Cancer - Journal of Thoracic Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2040423083/2053914361/gr1.jpg)
MET Signaling: Novel Targeted Inhibition and Its Clinical Development in Lung Cancer - Journal of Thoracic Oncology
![Mechanism of the Mesenchymal–Epithelial Transition and Its Relationship with Metastatic Tumor Formation | Molecular Cancer Research Mechanism of the Mesenchymal–Epithelial Transition and Its Relationship with Metastatic Tumor Formation | Molecular Cancer Research](https://mcr.aacrjournals.org/content/molcanres/9/12/1608/F2.large.jpg)
Mechanism of the Mesenchymal–Epithelial Transition and Its Relationship with Metastatic Tumor Formation | Molecular Cancer Research
![Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study - The Lancet Oncology Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/b1d3b867-74ab-4cf1-aad3-4997ae2f92eb/gr1.gif)
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study - The Lancet Oncology
![Cancer-Associated Fibroblasts Regulate Tumor-Initiating Cell Plasticity in Hepatocellular Carcinoma through c-Met/FRA1/HEY1 Signaling - ScienceDirect Cancer-Associated Fibroblasts Regulate Tumor-Initiating Cell Plasticity in Hepatocellular Carcinoma through c-Met/FRA1/HEY1 Signaling - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2211124716304326-fx1.jpg)